Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05033756
Title Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO)
Acronym COMPRENDO
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Institut fuer Frauengesundheit
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Department of Gynecology, Tübingen University Hospital NOT_YET_RECRUITING Tübingen Baden-Württemberg 72076 Germany Details
University Hospital Ulm NOT_YET_RECRUITING Ulm Baden-Württemberg 89075 Germany Details
Department of Gynecology and Obstetrics, Erlangen University Hospital RECRUITING Erlangen Bavaria 91054 Germany Details
Marienhospital Bottrop NOT_YET_RECRUITING Bottrop North Rhine Westphalia 46236 Germany Details
University Hospital Düsseldorf NOT_YET_RECRUITING Düsseldorf North Rhine Westphalia 40225 Germany Details
Helios-Klinikum Berlin-Buch RECRUITING Berlin 13125 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field